These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32600534)

  • 1. Management of Metastatic Renal Cell Carcinoma with Variant Histologies.
    Flippot R; Damarla V; McGregor BA
    Urol Clin North Am; 2020 Aug; 47(3):319-327. PubMed ID: 32600534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.
    Westerman ME; Shapiro DD; Wood CG; Karam JA
    Urol Clin North Am; 2020 Aug; 47(3):329-343. PubMed ID: 32600535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the Management of Rare Kidney Cancers.
    Giles RH; Choueiri TK; Heng DY; Albiges L; Hsieh JJ; Linehan WM; Pal S; Maskens D; Paseman B; Jonasch E; Malouf G; Molina AM; Pickering L; Shuch B; Srinivas S; Srinivasan R; Tannir NM; Bex A
    Eur Urol; 2017 Dec; 72(6):974-983. PubMed ID: 28720391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
    Ghandour RA; Singla N; Margulis V
    Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of prognostic factors in patients with metastatic renal cell carcinoma.
    Teishima J; Inoue S; Hayashi T; Matsubara A
    Int J Urol; 2019 Jun; 26(6):608-617. PubMed ID: 30959579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
    Shinohara N; Abe T
    Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
    Zhang T; Hwang JK; George DJ; Pal SK
    Cancer Treat Res Commun; 2020; 24():100183. PubMed ID: 32563923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?].
    Krege S
    Urologe A; 2020 Feb; 59(2):149-154. PubMed ID: 32076796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
    Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
    [No Abstract]   [Full Text] [Related]  

  • 11. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
    Reed JP; Posadas EM; Figlin RA
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
    Tomita Y
    Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
    Biles MJ; Patel HD; Allaf ME
    Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies for non-clear renal cell carcinoma.
    Singer EA; Bratslavsky G; Linehan WM; Srinivasan R
    Target Oncol; 2010 Jun; 5(2):119-29. PubMed ID: 20680492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
    Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
    Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
    Stewart GD; Aitchison M; Bex A; Larkin J; Lawless C; Méjean A; Nathan P; Oades G; Patard JJ; Paul J; Ravaud A; Escudier B;
    Eur Urol; 2017 Jun; 71(6):845-847. PubMed ID: 27815086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
    Mano R; Gopal N; Hakimi AA
    Curr Opin Urol; 2019 Sep; 29(5):531-539. PubMed ID: 31313716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
    Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
    Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma.
    Kapoor A; Kim J; Goucher G; Hoogenes J
    Urol Clin North Am; 2020 Aug; 47(3):271-280. PubMed ID: 32600530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.